An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab
NCT04249713
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
Biomarker Samples Not Collected
Conditions
Hidradenitis Suppurativa
Interventions
DRUG:
Brodalumab
Sponsor
Rockefeller University